Cargando…
Construction of VSVΔ51M oncolytic virus expressing human interleukin-12
The use of oncolytic viruses (OVs) in combination with cytokines, such as IL-12, is a promising approach for cancer treatment that addresses the limitations of current standard treatments and traditional cancer immunotherapies. IL-12, a proinflammatory cytokine, triggers intracellular signaling path...
Autores principales: | Abdulal, Rwaa H., Malki, Jana S., Ghazal, Ezdehar, Alsaieedi, Ahdab A., Almahboub, Sarah A., Khan, Muhammad Yasir, Alsulaiman, Reem M., Ghaith, Mazen M., Abujamel, Turki S., Ganash, Magdah, Mahmoud, Ahmad Bakur, Alkayyal, Almohanad A., Hashem, Anwar M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225647/ https://www.ncbi.nlm.nih.gov/pubmed/37255540 http://dx.doi.org/10.3389/fmolb.2023.1190669 |
Ejemplares similares
-
Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia
por: Alhabbab, Rowa Y., et al.
Publicado: (2021) -
Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review
por: Moglan, Abdulaziz Molham, et al.
Publicado: (2023) -
Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
por: Alkayyal, Almohanad A., et al.
Publicado: (2023) -
SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients
por: Algaissi, Abdullah, et al.
Publicado: (2020) -
Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients
por: Hashem, Anwar M., et al.
Publicado: (2020)